or Try an Advanced Search...

    Technical Analysis for HUGE - FSD Pharma Inc. - Class B Subordinate Voting Shares

    Grade Last Price % Change Price Change
    F 0.32 1.27% 0.00
    HUGE closed up 1.27 percent on Friday, May 17, 2024, on 2.36 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical HUGE trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 1.27%
    Wide Bands Range Expansion 1.27%
    Down 3 Days in a Row Weakness 1.27%
    Oversold Stochastic Weakness 1.27%
    New 52 Week Closing Low Bearish -2.00%
    Older End-of-Day Signals for HUGE ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low 1 day ago
    Down 2 % 1 day ago
    Down 1% 1 day ago
    New 52 Week Low 1 day ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    HUGE Chart by TradingView
    Basic chart:

    Profile

    FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Cobourg, Canada.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Health Sciences Autoimmune Disease Cannabis Chronic Pain Central Nervous System Disorders Nervous System Disorders Medical Cannabis Bioenergy Cannabis In Canada Cannabinoid Skeletal System Antiemetics Musculoskeletal System Antioxidants

    Is HUGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
    Apr 30 FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
    Apr 22 FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
    Apr 17 FSD Pharma expands pipeline investigation to include weight loss and liver health products
    Apr 17 FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
    Apr 15 FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
    Apr 8 FSD Pharma receives Nasdaq notification regarding minimum bid price deficiency
    Apr 8 FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
    Apr 2 FSD Pharma GAAP EPS of -$0.46
    Mar 30 Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    See more HUGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.6799
    52 Week Low 0.3066
    Average Volume 303,009
    200-Day Moving Average 0.95
    50-Day Moving Average 0.55
    20-Day Moving Average 0.39
    10-Day Moving Average 0.35
    Average True Range 0.05
    RSI (14) 25.93
    ADX 42.7
    +DI 10.41
    -DI 24.06
    Chandelier Exit (Long, 3 ATRs) 0.39
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.50
    Lower Bollinger Band 0.28
    Percent B (%b) 0.18
    BandWidth 57.28
    MACD Line -0.07
    MACD Signal Line -0.07
    MACD Histogram 0.0043
    Fundamentals Value
    Market Cap 12.56 Million
    Num Shares 39.4 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -0.55
    Price-to-Sales 91.86
    Price-to-Book 2.28
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.35
    Resistance 3 (R3) 0.35 0.34 0.35
    Resistance 2 (R2) 0.34 0.33 0.34 0.35
    Resistance 1 (R1) 0.33 0.33 0.32 0.33 0.34
    Pivot Point 0.32 0.32 0.32 0.32 0.32
    Support 1 (S1) 0.31 0.31 0.30 0.31 0.29
    Support 2 (S2) 0.30 0.30 0.30 0.29
    Support 3 (S3) 0.28 0.30 0.29
    Support 4 (S4) 0.28